The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis
Abstract
Limited information is available on the activity of anti-retroviral drugs against human immunodeficiency virus type 2 (HIV-2) and simian immunodeficiency virus (SIV) strains to guide their use in treatment or prophylaxis. We evaluated the antiviral activity of 16 approved drugs and one experimental drug, AMD3100, against two wild-type HIV-2 (ROD and EHO) isolates, two strains of SIV (mac251 and B670), and two strains of simian–human immunodeficiency virus (SHIV) that contain the reverse transcriptase (RTSHIV) or envelope glycoprotein (SHIV89.6) of human immunodeficiency virus type 1 (HIV-1) in a SIV(mac239) background. Drug susceptibility was measured conventionally by the MT-4/MTT assay, and results were analysed as fold changes in 50% effective concentration (EC 50) relative to the EC 50 for HIV-1(III B). The nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine, lamivudine, stavudine, didanosine, zalcitabine and abacavir as well as the nucleotide reverse transcriptase inhibitor tenofovir retained full activity against all six viruses except for SIV and SHIV89.6 that showed low-level resistance to didanosine. The protease inhibitors (PIs) ritonavir, indinavir, saquinavir and nelfinavir were found to be active against some HIV-2 or SIV strains. However, a significant reduction in susceptibility was seen with indinavir against SHIV89.6 (3.3-fold), and with amprenavir against HIV-2(ROD) (8.8-fold). All viruses except for RTSHIV showed a >200-fold decrease in susceptibility for the non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine, delavirdine and efavirenz, indicating high-level resistance. AMD3100, a CXCR4 antagonist, was active against HIV-2 and SHIV89.6, a finding consistent with the use of the CXCR4 co-receptor by these isolates, but was inactive against SIV strains. In contrast, enfuvirtide (T-20) was active against SHIV89.6 but had reduced inhibitory activity against both HIV-2 and SIV strains predicting little therapeutic value against these viruses. These findings support the use of NRTIs, tenofovir, but not NNRTIs, for treating HIV-2-infected persons or for prophylaxis against HIV-2 and SIV. The clinical significance of the low-level resistance of HIV-2 and SIV to some PIs is unclear. Co-receptor antagonists such as AMD3100 show promising anti-HIV-2 therapeutic modalities. Both AMD3100 and enfuvirtide could be used for prophylaxis against SHIV89.6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barré-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Dauguet, C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., et al. (1983) · Science · doi:10.1126/science.6189183 · Cited by 7,038
Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, J., Safai, B., et al. (1984) · Science · doi:10.1126/science.6200936 · Cited by 3,641
Popovic, M., Sarngadharan, M. G., Read, E., & Gallo, R. C. (1984) · Science · doi:10.1126/science.6200935 · Cited by 3,535
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Self-citationRapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2
Horwitz, J. P., Chua, J., & Noel, M. (1964) · The Journal of Organic Chemistry · doi:10.1021/jo01030a546 · Cited by 348
Ren, J., Bird, L. E., Chamberlain, P. P., Stewart-Jones, G. B., Stuart, D. I., & Stammers, D. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222366699 · Cited by 201
Pauwels, R., Andries, K., Debyser, Z., Van Daele, P., Schols, D., Stoffels, P., De Vreese, K., Woestenborghs, R., Vandamme, A. M., & Janssen, C. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1711 · Cited by 191
Long-term Persistent Infection of Macaque Monkeys with the Simian Immunodeficiency Virus
Daniel, M. D., Letvin, N. L., Sehgal, P. K., Hunsmann, G., Schmidt, D. K., King, N. W., & Desrosiers, R. C. (1987) · Journal of General Virology · doi:10.1099/0022-1317-68-12-3183 · Cited by 159
Cited by
Antiviral drugs in current clinical use
De Clercq, E. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 947
Rolain, J.-M., Colson, P., & Raoult, D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.05.015 · Cited by 401
Moranguinho, I., Taveira, N., & Bártolo, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065905 · Cited by 37
Metadata
- Authors
- Witvrouw, M., Pannecouque, C., Switzer, W. M., Folks, T. M., Clercq, E. D., & Heneine, W.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2004-01
- Volume
- 9
- Issue
- 1
- Pages
- 57-65
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W170094209
- Cited by
- 271
- References
- 20
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis. https://app.cochat.ai/papers/10.1177/135965350400900115
- The paper
- Witvrouw, M., Pannecouque, C., Switzer, W. M., Folks, T. M., Clercq, E. D., & Heneine, W. (2004). Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure Prophylaxis. Antiviral Therapy. https://doi.org/10.1177/135965350400900115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.